文献速递心脑血管急症

急性冠脉综合征侵入性管理患者桡动脉与股动脉入路及比伐卢定与普通肝素的比较(MATRIX):多中心随机对照试验最终1年结果

Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial.
PubMed 文献 · Lancet · 2018-08-25
一句话结论急性冠脉综合征侵入性管理时桡动脉入路较股动脉入路降低1年净不良临床事件,作者认为桡动脉入路应成为默认入路。

MATRIX研究是在意大利、荷兰、西班牙和瑞典78家医院开展的嵌套随机多中心开放标签优效性试验,纳入8404例急性冠脉综合征患者,随机分为桡动脉入路(4197例)或股动脉入路(4207例);其中7213例进一步随机接受比伐卢定(3610例)或普通肝素(3603例),比伐卢定组再随机接受术后输注(1799例)或不输注(1811例)。1年时,桡动脉入路与股动脉入路的主要不良心血管事件无显著差异(14.2% vs 15.7%;率比0.89,95%CI 0.80-1.00;p=0.0526),但桡动脉入路净不良临床事件更少(15.2% vs 17.2%;率比0.87,95%CI 0.78-0.97;p=0.0128)。比伐卢定与肝素相比,主要不良心血管事件(15.8% vs 16.8%;率比0.94,95%CI 0.83-1.05;p=0.28)和净不良临床事件(17.0% vs 18.4%;率比0.91,95%CI 0.81-1.02;p=0.10)均无显著差异。术后比伐卢定输注与否,紧急靶血管血运重建、支架血栓或净不良临床事件的复合终点无差异(17.4% vs 17.4%;率比0.99,95%CI 0.84-1.16;p=0.90)。

要点

  • 急性冠脉综合征侵入性管理时,桡动脉入路较股动脉入路1年净不良临床事件更少(15.2% vs 17.2%;率比0.87,95%CI 0.78-0.97;p=0.0128)。
  • 桡动脉与股动脉入路1年主要不良心血管事件无显著差异(14.2% vs 15.7%;率比0.89,95%CI 0.80-1.00;p=0.0526)。
  • 比伐卢定与肝素相比1年主要不良心血管事件无显著差异(15.8% vs 16.8%;率比0.94,95%CI 0.83-1.05;p=0.28)。
  • 比伐卢定与肝素相比1年净不良临床事件无显著差异(17.0% vs 18.4%;率比0.91,95%CI 0.81-1.02;p=0.10)。
  • 比伐卢定术后输注与否1年复合终点无差异(17.4% vs 17.4%;率比0.99,95%CI 0.84-1.16;p=0.90)。

适用人群与场景

  • 急性冠脉综合征接受侵入性管理患者,包括ST段抬高型心肌梗死和非ST段抬高型急性冠脉综合征(肌钙蛋白阳性或阴性)。
  • ST段抬高型心肌梗死患者在冠状动脉造影前同时随机分配至桡动脉或股动脉入路及比伐卢定或肝素(一步纳入)。
  • 非ST段抬高型急性冠脉综合征患者在冠状动脉造影前随机分配入路,造影后判断适合经皮冠状动脉介入治疗者才进入抗凝血酶类型和治疗时长程序(两步纳入)。

处置流程与药物剂量

  • 比伐卢定:0.75 mg/kg 静脉弹丸注射,随后立即以 1.75 mg/kg/h 静脉输注至经皮冠状动脉介入治疗完成。
  • 普通肝素:未接受糖蛋白IIb/IIIa抑制剂者 70-100 单位/kg;接受糖蛋白IIb/IIIa抑制剂者 50-70 单位/kg。
  • 比伐卢定组患者随机接受术后输注或不输注。
  • 随机化按计划新用或当前使用P2Y12抑制剂(氯吡格雷 vs 替格瑞洛或普拉格雷)及急性冠脉综合征类型分层。

研究设计与关键结果

  • MATRIX为嵌套三个随机、多中心、开放标签、优效性试验,在意大利、荷兰、西班牙和瑞典78家医院纳入8404例急性冠脉综合征患者。
  • 8404例随机分为桡动脉入路4197例或股动脉入路4207例;其中7213例随机接受比伐卢定3610例或肝素3603例;比伐卢定组再随机分为术后输注1799例或不输注1811例。
  • 1年主要不良心血管事件(全因死亡、心肌梗死或卒中复合终点):桡动脉组14.2% vs 股动脉组15.7%(率比0.89,95%CI 0.80-1.00;p=0.0526),无显著差异。
  • 1年净不良临床事件(非冠脉旁路移植相关大出血或主要不良心血管事件复合终点):桡动脉组15.2% vs 股动脉组17.2%(率比0.87,95%CI 0.78-0.97;p=0.0128),桡动脉组更少。
  • 1年主要不良心血管事件:比伐卢定组15.8% vs 肝素组16.8%(率比0.94,95%CI 0.83-1.05;p=0.28),无显著差异。
  • 1年净不良临床事件:比伐卢定组17.0% vs 肝素组18.4%(率比0.91,95%CI 0.81-1.02;p=0.10),无显著差异。
  • 1年紧急靶血管血运重建、支架血栓或净不良临床事件复合终点:术后输注组17.4% vs 不输注组17.4%(率比0.99,95%CI 0.84-1.16;p=0.90),无显著差异。

证据类型、等级与局限

  • 证据类型:多中心随机对照试验(嵌套三个试验),开放标签,优效性设计,意向性治疗分析。
  • 作者结论:桡动脉入路较股动脉入路降低1年净不良临床事件,但未降低主要不良心血管事件;比伐卢定伴或不伴术后输注未降低主要不良心血管事件或净不良临床事件。
  • 作者建议:桡动脉入路应成为急性冠脉综合征侵入性管理患者的默认入路。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 急性冠脉综合征侵入性管理时,作者认为桡动脉入路应成为默认入路,因1年净不良临床事件较股动脉入路更少(15.2% vs 17.2%;率比0.87,95%CI 0.78-0.97)。
  • 比伐卢定与肝素在1年主要不良心血管事件和净不良临床事件上无显著差异,比伐卢定术后输注与否复合终点无差异。
  • 比伐卢定给药方案为0.75 mg/kg静脉弹丸注射后1.75 mg/kg/h输注至经皮冠状动脉介入治疗完成;肝素剂量按是否接受糖蛋白IIb/IIIa抑制剂调整。

指南或共识出处

  • MATRIX试验(Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox),ClinicalTrials.gov注册号NCT01433627。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox (MATRIX) programme was designed to assess the comparative safety and effectiveness of radial versus femoral access and of bivalirudin versus unfractionated heparin with optional glycoprotein IIb/IIIa inhibitors in patients with the whole spectrum of acute coronary syndrome undergoing invasive management. Here we describe the prespecified final 1-year outcomes of the entire programme.

METHODS: MATRIX was a programme of three nested, randomised, multicentre, open-label, superiority trials in patients with acute coronary syndrome in 78 hospitals in Italy, the Netherlands, Spain, and Sweden. Patients with ST-elevation myocardial infarction were simultaneously randomly assigned (1:1) before coronary angiography to radial or femoral access and to bivalirudin, with or without post-percutaneous coronary intervention infusion or unfractionated heparin (one-step inclusion). Patients with non-ST-elevation acute coronary syndrome were randomly assigned (1:1) before coronary angiography to radial or femoral access and, only if deemed eligible to percutaneous coronary intervention after angiography (two-step inclusion), entered the antithrombin type and treatment duration programmes. Randomisation sequences were computer generated, blocked, and stratified by intended new or current use of P2Y12 inhibitor (clopidogrel vs ticagrelor or prasugrel), and acute coronary syndrome type (ST-elevation myocardial infarction, troponin-positive, or troponin-negative non-ST-elevation acute coronary syndrome). Bivalirudin was given as a bolus of 0·75 mg/kg, followed immediately by an infusion of 1·75 mg/kg per h until completion of percutaneous coronary intervention. Heparin was given at 70-100 units per kg in patients not receiving glycoprotein IIb/IIIa inhibitors, and at 50-70 units per kg in patients receiving glycoprotein IIb/IIIa inhibitors. Clinical follow-up was done at 30 days and 1 year. Co-primary outcomes for MATRIX access and MATRIX antithrombin type were major adverse cardiovascular events, defined as the composite of all-cause mortality, myocardial infarction, or stroke up to 30 days; and net adverse clinical events, defined as the composite of non-coronary artery bypass graft-related major bleeding, or major adverse cardiovascular events up to 30 days. The primary outcome for MATRIX treatment duration was the composite of urgent target vessel revascularisation, definite stent thrombosis, or net adverse clinical events up to 30 days. Analyses were done according to the intention-to-treat principle. This trial is registered with ClinicalTrials.gov, number NCT01433627.

FINDINGS: Between Oct 11, 2011, and Nov 7, 2014, we randomly assigned 8404 patients to receive radial (4197 patients) or femoral (4207 patients) access. Of these 8404 patients, 7213 were included in the MATRIX antithrombin type study and were randomly assigned to bivalirudin (3610 patients) or heparin (3603 patients). Patients assigned to bivalirudin were included in the MATRIX treatment duration study, and were randomly assigned to post-procedure infusion (1799 patients) or no post-procedure infusion (1811 patients). At 1 year, major adverse cardiovascular events did not differ between patients assigned to radial access compared with those assigned to femoral access (14·2% vs 15·7%; rate ratio 0·89, 95% CI 0·80-1·00; p=0·0526), but net adverse clinical events were fewer with radial than with femoral access (15·2% vs 17·2%; 0·87, 0·78-0·97; p=0·0128). Compared with heparin, bivalirudin was not associated with fewer major adverse cardiovascular (15·8% vs 16·8%; 0·94, 0·83-1·05; p=0·28) or net adverse clinical events (17·0% vs 18·4%; 0·91, 0·81-1·02; p=0·10). The composite of urgent target vessel revascularisation, stent thrombosis, or net adverse clinical events did not differ with or without post-procedure bivalirudin infusion (17·4% vs 17·4%; 0·99, 0·84-1·16; p=0·90).

INTERPRETATION: In patients with acute coronary syndrome, radial access was associated with lower rates of net adverse clinical events compared with femoral access, but not major adverse cardiovascular events at 1 year. Bivalirudin with or without post-procedure infusion was not associated with lower rates of major adverse cardiovascular events or net adverse clinical events. Radial access should become the default approach in acute coronary syndrome patients undergoing invasive management.

FUNDING: Italian Society of Invasive Cardiology, The Medicines Company, Terumo, amd Canada Research Chairs Programme.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Valgimigli M, Frigoli E, Leonardi S, et al. Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. Lancet. 2018. PMID: 30153988. doi:10.1016/S0140-6736(18)31714-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。